Home
Resources
Publications
Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau

Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau

Hyeanjeong Jeong, Seulgi Shin, Jun-Seok Lee, Soo Hyun Lee, Ja-Hyun Baik, Sungsu Lim, Yun Kyung Kim

Int J Mol Sci. 2019 Sep 1;20(17):4283.

PMID: 31480543

Abstract:

Epigenetic remodeling via histone acetylation has become a popular therapeutic strategy to treat Alzheimer's disease (AD). In particular, histone deacetylase (HDAC) inhibitors including M344 and SAHA have been elucidated to be new drug candidates for AD, improving cognitive abilities impaired in AD mouse models. Although emerged as a promising target for AD, most of the HDAC inhibitors are poorly selective and could cause unwanted side effects. Here we show that tau is one of the cytosolic substrates of HDAC and the treatment of HDAC inhibitors such as Scriptaid, M344, BML281, and SAHA could increase the level of acetylated tau, resulting in the activation of tau pathology.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP251456607-B	M344		251456-60-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: